Company Profile
Alvotech Stock Price, News & Analysis
- Ticker:
- ALVO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Iceland
Stock performance
3.80 USD (+1.06%)
Close
Last updated: August 6, 2026
936M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ALVO closed up 1.06% at $3.80. No new same-company headline was identified in the current news window.
Company overview
Business overview
Alvotech is a biosimilars company developing and manufacturing lower-cost alternatives to complex biologic medicines.
Geographic Base and Sector Classification
Headquartered in Iceland and listed on NASDAQ, Alvotech has a global biosimilar footprint.
Business Model Characteristics
The company relies on manufacturing execution, regulatory approvals, and commercial launches across biosimilar markets.
Position Within the Biotechnology Landscape
Alvotech sits in the biosimilar segment where scale, regulatory success, and manufacturing discipline matter most.
Future catalysts
Alvotech's catalysts are biosimilar launches, partner rollouts, and any approval that helps the company keep scaling its complex-antibody portfolio. The business is all about execution across multiple biosimilar assets.
Recent news
- 01
- 02
- 03
Viðskipti stjórnenda og tengdra aðila
Source: Alvotech
- 04
Transactions of Managers and Closely Associated Persons
Source: Alvotech
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Alvotech (ALVO)?
Alvotech (ALVO) most recently closed at 3.80 USD, a +1.06% move versus the previous session.
What is the market cap of Alvotech (ALVO)?
Alvotech currently has a market capitalization of 936M USD on BioPharmSignal.
What does Alvotech do?
Alvotech is a biosimilars company developing and manufacturing lower-cost alternatives to complex biologic medicines.
On which exchange is ALVO stock listed?
Alvotech (ALVO) is associated with NASDAQ, Iceland, Biopharma.
What is Alvotech?
Alvotech's catalysts are biosimilar launches, partner rollouts, and any approval that helps the company keep scaling its complex-antibody portfolio.
Which conditions is Alvotech targeting with Alvotech?
Alvotech's catalysts are biosimilar launches, partner rollouts, and any approval that helps the company keep scaling its complex-antibody portfolio.
How does Alvotech describe recent progress with Alvotech?
Alvotech's catalysts are biosimilar launches, partner rollouts, and any approval that helps the company keep scaling its complex-antibody portfolio.
What future catalysts are investors watching for Alvotech?
Alvotech's catalysts are biosimilar launches, partner rollouts, and any approval that helps the company keep scaling its complex-antibody portfolio. The business is all about execution across multiple biosimilar assets.